Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Opening of US Laboratory

Published: Thursday, March 06, 2014
Last Updated: Thursday, March 06, 2014
Bookmark and Share
Laboratory will support the expansion of Epistem's contract research division.

Epistem Holdings Plc has announced that it has opened a US laboratory based in Baltimore, Maryland. The laboratory will support the expansion of Epistem's contract research division within the US.

The US laboratory is currently offering histology and immunohistochemistry (IHC) services to a range of US clients, expanding upon the success of the GcLP and GLP compliant UK laboratory.

The experienced and skilled technical team have already developed IHC protocols for a panel of over 150 antibodies which are available to clients worldwide.

Epistem Co-Founder and Director of the Contract Services Business, Dr Catherine Booth commented "Epistem's specialist contract research services provide valuable support to drug discovery and development pipelines. We already have strong relationships with both companies, academic and government groups on the East Coast along with a US Business team based in Boston and Baltimore. We are excited to now be providing services locally to support this growing US business".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem Announces Further Partnership With The University of Manchester
Partnership will allow the Company to expand its existing range of wound healing models.
Tuesday, April 22, 2014
Epistem Announces Evaluation of Genedrive® for Pathogen Detection
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.
Thursday, January 16, 2014
Epistem Presents GenetRx™ Clinical Data from Two Recently Completed Studies
Data presented on the use of scalp hair to assess androgen receptor directed therapies and to identify novel pharmacodynamic markers for an antisense molecule.
Thursday, November 12, 2009
Epistem Presents Further Data Supporting its Plucked Hair Biomarker Technology
Data on the effects of Gemcitabine on epithelial tissue released at the Institute of Cancer Research Centenary Conference.
Thursday, June 11, 2009
Epistem to Present Erlotinib Biomarker Data at AACR Meeting
Epistem plc will present results from its recently completed preclinical plucked hair biomarker study.
Wednesday, April 15, 2009
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!